We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
- Authors
Bhatia, Vipul; Kamat, Nikhil V.; Pariva, Tiffany E.; Wu, Li-Ting; Tsao, Annabelle; Sasaki, Koichi; Sun, Huiyun; Javier, Gerardo; Nutt, Sam; Coleman, Ilsa; Hitchcock, Lauren; Zhang, Ailin; Rudoy, Dmytro; Gulati, Roman; Patel, Radhika A.; Roudier, Martine P.; True, Lawrence D.; Srivastava, Shivani; Morrissey, Colm M.; Haffner, Michael C.
- Abstract
Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 relative to prostate-specific membrane antigen (PSMA) in lethal metastatic prostate cancers and the development of a STEAP1-directed chimeric antigen receptor (CAR) T cell therapy. STEAP1 CAR T cells demonstrate reactivity in low antigen density, antitumor activity across metastatic prostate cancer models, and safety in a human STEAP1 knock-in mouse model. STEAP1 antigen escape is a recurrent mechanism of treatment resistance and is associated with diminished tumor antigen processing and presentation. The application of tumor-localized interleukin-12 (IL-12) therapy in the form of a collagen binding domain (CBD)-IL-12 fusion protein combined with STEAP1 CAR T cell therapy enhances antitumor efficacy by remodeling the immunologically cold tumor microenvironment of prostate cancer and combating STEAP1 antigen escape through the engagement of host immunity and epitope spreading. Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a highly enriched cell surface antigen expressed in prostate cancer. Here the authors describe the design of STEAP1 directed CART cells and show their antitumor activity in preclinical models of prostate cancer, also in combination with a collagen binding domain-IL-12 fusion cytokine.
- Subjects
CHIMERIC antigen receptors; ANDROGEN receptors; T cells; CELL surface antigens; T cell receptors; PROSTATE cancer; CELL fusion; TUMOR antigens; CHIMERIC proteins
- Publication
Nature Communications, 2023, Vol 14, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-023-37874-2